Health
Neurophet Signs MOU with ALZ-NET to Facilitate Imaging Monitoring Infrastructure for Alzheimer's Disease Therapies
Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced today that it has signed a memorandum of understanding (MOU) with the Alzheimer's Network for Treatment and Diagnostics (ALZ-NET).
About this update from Neurophet, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Aims to improve quality of care for patients with Alzheimer's disease… Exploring adoption of Neurophet's key solutions","length":126,"tagName":"p"}]},{"val":[{"type":"text","content":"Collaboration expected to leverage Neurophet AQUA, Neurophet SCALE PET and Neurophet AQUA AD Plus","length":97,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":223,"olType":false},{"type":"text","content":"SEOUL, South Korea, March 26, 2026 /PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced today that it has signed a memorandum of understanding (MOU) with the Alzheimer's Network for Treatment and Diagnostics (ALZ-NET).","length":345,"tagName":"p"},{"type":"image","alt":"Neurophet Signs MOU with ALZ-NET","displaySize":"","headline":null,"caption":"Neurophet Signs MOU with ALZ-NET","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":68,"url":"https://media.zenfs.com/en/prnewswire.com/531521a3948630958a4173b0afed74d6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6HCpbGk3dlyW6eeIi1W7uQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEyMA--/https://media.zenfs.com/en/prnewswire.com/531521a3948630958a4173b0afed74d6","width":400,"height":68}},"href":"https://mma.prnewswire.com/media/2937674/Neurophet_Signs_MOU_with_ALZ_NET.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The agreement aims to support healthcare professionals participating in ALZ-NET and enhance the quality of care for patients with Alzheimer's disease. Under the partnership, the two parties will work to raise awareness of the importance of monitoring Amyloid-Related Imaging Abnormalities (ARIA), while also providing discounted access to Neurophet's key solutions across medical institutions participating in ALZ-NET and expanding their clinical utilization.","length":467,"tagName":"p"},{"type":"text","content":"The collaboration will involve Neurophet's flagship solutions, including Neurophet AQUA, a brain neurodegeneration imaging analysis software; Neurophet SCALE PET, a quantitative Positron Emission Tomography (PET) imaging analysis software; Neurophet AQUA AD Plus, an integrated brain imaging analysis solution designed to support treatment de...